GLENMARK PHARMACEUTICALS LTD. - 532296 - Shareholding for the Period Ended December 31, 2018
Glenmark Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2018. For more details, kindly Click here Glenmark inks pact with South Korea's Yuhan Corp to commercialise Ryaltris
Drug major Glenmark Pharmaceuticals on Thursday said its Suisse subsidiary Glenmark Specialty S.A. has entered into an exclusive licensing agreement Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals enters into an Exclusive Licensing Agreement with Yuhan Corporation for commercializing Investigational Seasonal Allergic Rhinitis Nasal Spray Ryaltris in South Korea Dear Sir, With reference to the subject mentioned above, kindly find attached media release which is self explanatory. Request you to kindly take the same on record. Thanking you, Glenmark eyes up to 15 per cent revenue growth over 3-5 years
Glenmark plans to focus on out-licensing of the NME assets Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: J. P. Morgan Healthcare Conference, San Francisco, USA - Presentation Dear Sir, Kindly find enclosed herewith the presentation that will be made at the J. P. Morgan Healthcare Conference, San Francisco, USA. The same will also be made available on our website. Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Update on Innovative R&D; Capabilities and Pipeline Overview Kindly find enclosed herewith the presentation on update on Innovative R&D; Capabilities and Pipeline Overview. The same will also be made available on our website. Glenmark Pharmaceuticals Ltd - 532296 - Completion Of Transfer Of Company''s Active Pharmaceuticals Ingredient (API) Business.
Dear Sirs, Subject: Completion of transfer of Company''s Active Pharmaceuticals Ingredient (API) Business. Further to the earlier intimation dated October 9, 2018, we hereby inform you that transfer of the Company's API business to Glenmark Life Sciences Limited, a wholly owned subsidiary of the Company, has been completed on December 31, 2018. Request you to kindly take note of the same. Thanking You. Glenmark forays into branded dermatology segment in US
Glenmark Pharmaceuticals on Wednesday announced its foray into the branded dermatology segment in the United States.The branded portfolio for the US m Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals Announces Entry into Branded Dermatology Segment in the United States With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Request you to kindly take the same on record. Glenmark Pharma gets USFDA nod for ear drops
Glenmark Pharmaceuticals on Tuesday said it has received final approval from the US health regulator for Fluocinolone Acetonide Oil, used to treat ec